Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

NEW YORK--(BUSINESS WIRE)--HDFC Bank Limited (NYSE: HDB) filed its Form 20-F for the year ended March 31, 2026 on July 15, 2026....

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Le partenaire de Medincell (Euronext Paris : MEDCL), Teva Pharmaceuticals (NYSE et TASE: TEVA), a annoncé aujourd’hui que les ventes nettes d’UZEDY® aux États-Unis ont atteint un niveau record de 77 M$ au deuxième trimestre 2026, soit une progression de +43 % sur un an. Teva a relevé ses prévisions de ventes pour UZEDY® en 2026, désormais attendues entre 270 et 290 M$, contre 250-280 M$ précédemment. Selon Teva, sur la base des données d’IQ...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

东京--(BUSINESS WIRE)--(美国商业资讯)-- Kioxia Corporation今日宣布推出KIOXIA NX1系列固态硬盘（SSD），这是新一代E1.S PCIe®® 5.0 NVMe™数据中心级固态硬盘，也是Kioxia首款支持直接液冷的固态硬盘。KIOXIA NX1系列采用了Kioxia自主研发的下一代控制器架构，不仅提供当前的独特功能，还为未来功能的扩展奠定了基础。该系列新硬盘专为配备GPU的服务器和超大规模数据中心环境设计，旨在提供高性能、高能效的存储解决方案。 KIOXIA NX1系列是KIOXIA XD系列的继任产品，凭借PCIe®5.0 的性能优势，助力云服务提供商和超大规模运营商在保持运营效率的同时优化基础设施。与上一代产品1相比，KIOXIA NX1固态硬盘的顺序写入性能最高提升约38%，随机写入性能最高提升约 20%2。 随着人工智能基础设施的持续扩展，存储系统必须跟上日益提高的密度、加速器密集型服务器设计的发展步伐。E1.S外形规格有助于最大限度地提高存储密度，同时支持先进的热管理方案，包括兼容冷板的直接液冷配置，可在高性能人工智能服务器环境...

TORONTO--(BUSINESS WIRE)--VoxNeuro receives FDA 510(k) clearance for cfNI software and engages Stillwater Capital to explore strategic partnerships....

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

TAIPEI, Taiwan--(BUSINESS WIRE)--United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC” or “The Company”), a leading global semiconductor foundry, today announced its consolidated operating results for the second quarter of 2026. Second quarter consolidated revenue was NT$68.73 billion, increasing 12.6% from NT$61.04 billion in 1Q26. Compared to a year ago, 2Q26 revenue increased 17.0%. Consolidated gross margin for 2Q26 was 32.5%. Net income attributable to the shareholders of the...